Evidence map›Paper›PMID 29332037›Full record

ArticleJournal of Alzheimer's disease : JAD2018

Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.

Andrew Arner, Edward Rockenstein, Michael Mante, Jazmin Florio, Deborah Masliah, Bahar Salehi, Anthony Adame, Cassia Overk, Eliezer Masliah, Robert A Rissman

Expression of concernOpen access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Age-Dependent Behavioral and Metabolic Assessment ofFrontiers in molecular neuroscience · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Andrew ArnerDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Edward RockensteinDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Michael ManteDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Jazmin FlorioDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Deborah MasliahDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Bahar SalehiDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Anthony AdameDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Cassia OverkDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Eliezer MasliahDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Robert A RissmanDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

TRAINING IN THE NEUROPLASTICITY OF AGINGT32AG000216 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOO, EDWARD H. · 1992 to 2017
$8.4M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
Proinflammatory Endophenotype to predict NSAID treatment response Alzheimer's trialsR01AG051848 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LYKETSOS, CONSTANTINE G, O'BRYANT, SID E · 2016 to 2020
$3.7M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
Pathogenicity of neuronally-derived tau in exosomesR21AG051839 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2016 to 2017
$426k
Validation Studies of CRF Receptor 1 as a Target for ADI01BX003040 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RISSMAN, ROBERT · 2016 to 2020
–
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBII01BX004312 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RISBROUGH, VICTORIA B, RISSMAN, ROBERT · 2019 to 2022
–
BLRD VA I01 BX003040BLRD VA I01 BX004312NIA NIH HHS R01 AG018440NIA NIH HHS R01 AG051848NIA NIH HHS R21 AG051839NIA NIH HHS R37 AG018440NIA NIH HHS T32 AG000216
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common tauopathy, characterized by progressive accumulation of amyloid-β (Aβ) and hyperphosphorylated tau. While pathology associated with the 4-repeat (4R) tau isoform is more abundant in corticobasal degeneration and progressive supranuclear palsy, both 3R and 4R tau isoforms accumulate in AD. Many studies have investigated interactions between Aβ and 4R tau in double transgenic mice, but few, if any, have examined the effects of Aβ with 3R tau. To examine this relationship, we crossed our APP751 mutant line with our recently characterized 3R tau mutant model to create a bigenic line (hAPP-3RTau) to model AD neuropathology. Mice were analyzed at 3 and 6 months of age for pathological and behavioral endpoints. While both the 3RTau and the hAPP-3RTau mice showed neuronal loss, increased tau aggregation, Aβ plaques and exhibited more behavioral deficits compared to the non-tg control, the bigenic mice often displaying relatively worsening levels. We found that even in young animals we found that the presence of APP/Aβ increased the accumulation of 3R tau in the neocortex and hippocampus. This observation was accompanied by activation of GSK3 and neurodegeneration in the neocortex and CA1 region. These results suggest that in addition to 4R tau, APP/Aβ may also enhance accumulation of 3R tau, a process which may be directly relevant to pathogenic pathways in AD. Our results demonstrate that this bigenic model closely parallels the pathological course of AD and may serve as a valuable model for testing new pharmacological interventions.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsDisease Models, AnimalFemaleGlycogen Synthase Kinase 3HippocampusHumansMaleMiceMice, TransgenicNeocortexTauopathiestau ProteinsAmyloid beta-PeptidesGlycogen Synthase Kinase 3tau Proteins3R tauAlzheimer’s diseaseamyloid-βhippocampusmousePick’s diseasetau phosphorylationtransgenic

Identifiers

PMID29332037
PMCPMC6508863
OpenAlexW2783916250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.